Bio NC
Filter News
Found 17,875 articles
-
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
3/18/2024
Fennec Pharmaceuticals Inc. and Norgine announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand.
-
Parexel Announces CEO Succession PlanChief Operating & Growth Officer Peyton Howell to succeed Jamie Macdonald effective May 15, 2024
3/18/2024
Parexel today announced that Jamie Macdonald will retire and transition his role as Chief Executive Officer (CEO) to the company’s Chief Operating and Growth Officer Peyton Howell effective May 15, 2024.
-
Dignify Therapeutics Announces Anthony DiTonno as Chief Executive Officer
3/18/2024
Dignify Therapeutics, a pharmaceutical and medical device development company focused on restoring bowel and bladder control for elderly and neurologically impaired individuals, announced that Anthony DiTonno has been named as Chief Executive Officer.
-
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
3/18/2024
Humacyte, Inc. will release its financial results for the fourth quarter and year ended December 31, 2023, on Friday, March 22, 2024.
-
Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer
3/16/2024
Labcorp, a global leader of innovative and comprehensive laboratory services, presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer.
-
Asensus Surgical, Inc. Schedules Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call for March 21, 2024
3/15/2024
Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and the patient, announced that it plans to release fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, March 21, 2024.
-
Inhalon Biopharma Announces Two Publications Advancing its Inhaled Antibody Treatment Platform for Acute Respiratory Infections
3/14/2024
Inhalon Biopharma today announced the publication of preclinical data showcasing the advantages and efficacy of its “muco-trapping” technology in animal models of respiratory syncytial virus (RSV) and SARS-CoV-2 infections.
-
Glioblastoma Foundation to Be Official Charity Partner of the 2024 Los Angeles Marathon
3/14/2024
The Glioblastoma Foundation is proud to be a charity partner for the 2024 Los Angeles Marathon for the 5th year.
-
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
3/13/2024
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.
-
Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
3/13/2024
Atsena Therapeutics announced dosing has been initiated in the second cohort of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis.
-
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
3/13/2024
Pfizer Inc. announced that the European Commission has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.
-
BioSkryb Launches New Whole Genome and Transcriptome Core Kits to Accelerate Single-Cell Multiomics
3/13/2024
BioSkryb Genomics announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.
-
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
3/12/2024
Pfizer Inc. announced that a Phase 3 study of the antibody-drug conjugate ADCETRIS® in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma showed a statistically significant and clinically meaningful improvement in overall survival compared to lenalidomide and rituximab plus placebo.
-
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
3/12/2024
Bioventus Inc., a global leader in innovations for active healing, announced fourth quarter and full-year financial results for the year ended December 31, 2023, and provided its financial guidance for full-year 2024.
-
Innovaccer Announces Acquisition of Pharmacy Quality Solutions to Accelerate Value-Based Care in Pharmacy Settings
3/12/2024
Innovaccer, a leading healthcare company, has announced the completion of its acquisition of Pharmacy Quality Solutions, a leader in Pharmacy-Payer performance technology.
-
Scorpius Holdings, Inc. Announces Closing of Public Offering - March 12, 2024
3/12/2024
Scorpius Holdings, Inc., an integrated contract development and manufacturing organization, announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for gross proceeds of $1,500,000, before deducting underwriting discounts and offering expenses.
-
Alcami Partners with Tanvex CDMO to Offer a Complete Solution for Biologics Developers
3/12/2024
Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced a new strategic partnership with Tanvex CDMO, a biologics developer offering pre-clinical to commercial biologic CDMO services.
-
Tenax Therapeutics to Present at the 36th Annual Roth Conference
3/12/2024
Tenax Therapeutics, Inc. today announced that it will participate in the 36th Annual Roth Conference in Dana Point, California, from March 17-19, 2024.
-
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
3/11/2024
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the issue of a new U.S. patent covering Talicia1 as an all-in-one fixed-dose combination of amoxicillin, omeprazole and rifabutin and its use for the treatment of helicobacter pylori infection.
-
Fortrea Reports Fourth Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
3/11/2024
Fortrea, a leading global contract research organization, reported financial results for the fourth quarter and full year ended December 31, 2023.